ImmunityBio (IBRX) Receivables - Net (2014 - 2026)

ImmunityBio (IBRX) has 8 years of Receivables - Net data on file, last reported at $43.3 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $43.3 million, up 154.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.3 million (up 154.1% YoY), and the FY2025 annual result was $42.6 million, up 1703.86% from the prior year.
• Receivables - Net grew to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
• Over five years, Receivables - Net peaked at $43.3 million in Q1 2026 and troughed at $600000.0 in Q2 2023.
• A 5-year average of $14.0 million and a median of $3.3 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net jumped 72.17% in 2024, then surged 2332.71% in 2025.
• A 5-year view of Receivables - Net shows it stood at $1.3 million in 2022, then slumped by 30.77% to $900000.0 in 2023, then surged by 162.22% to $2.4 million in 2024, then surged by 1703.86% to $42.6 million in 2025, then climbed by 1.64% to $43.3 million in 2026.
• Business Quant data shows IBRX's Receivables - Net at $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $32.0 million in Q3 2025.